[News Article]``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2``...
`` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model``...
Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018.
Title
Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2" is now indexed on PubMed.
PharmAbcine, a clinical stage immune-oncology company, today announced that "Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2" is now indexed on PubMed.
Link to your paper on PubMed: http://www.ncbi.nlm.nih.gov/pubmed/29563774